Patent ID: 9579382
Date: 2017-02-28
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method of treating cancer in a human subject in need thereof, which comprises: administering to the subject, by systemic administration, an effective plurality of doses of a recombinant human LAG-3 protein or a derivative thereof, wherein the recombinant human LAG-3 protein comprises an extracellular region having the first, second, third and fourth immunoglobulin-like domains of a native human LAG-3 protein and the derivative is selected from the group consisting of: i) a fragment of the native human LAG-3 protein comprising the first and second immunoglobulin-like domains of the native human LAG-3 protein; ii) a fragment of the native human LAG-3 protein comprising the first, second, third and fourth immunoglobulin-like domains of the native human LAG-3 protein; iii) a mutant form of the native human LAG-3 protein, or a fragment thereof that comprises the first and second immunoglobulin-like domains of the native human LAG-3 protein, wherein the mutant comprises a substitution of an amino acid at one or more of the following positions: a) position 73 where ARG is substituted with GLU, b) position 75 where ARG is substituted with ALA or GLU, c) position 76 where ARG is substituted with GLU, iv) a variant of the native human LAG-3 protein comprising the first, second, and third immunoglobulin-like domains of the native human LAG-3 protein; and v) a recombinant soluble human LAG-3Ig fusion protein (IMP321) comprising at least the first and second immunoglobulin-like domains of the native human LAG-3 protein fused to human IgG1 Fc; wherein the recombinant human LAG-3 protein or the derivative thereof is the sole active ingredient in said treatment, and wherein each dose of the recombinant human LAG-3 protein or the derivative thereof is 1-30 mg of the recombinant soluble human LAG-3Ig fusion protein IMP321, or a molar equivalent of 1-30 mg of IMP321; inducing a systemic increase in the number of monocytes in blood of the subject; and eliciting a systemic monocyte-mediated immune response.